Monograph Capital is a venture capital firm that focuses on funding innovative life sciences companies, aiming to translate promising scientific discoveries into life-changing treatments globally. Their strategy involves leveraging deep medical expertise, extensive pharmaceutical relationships, and seasoned operational experience to build value for their partners and investors.
83% of their portfolio is in Biotech & Life Sciences. Deal activity increased 100% year-over-year (2 deals in the last 12 months). Their most common stage is series-a (83% of deals). Average disclosed round size is $72.2M (across 6 rounds with reported amounts).
Portfolio
6
Fund Size
—
Top Stage
Series A
Last 12 Mo
2
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
6 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Prolynx | Series A | $70M | Dec 2025 |
 Elevara Medicines | Series A | $70M | Sep 2025 |
 Ouro Medicines | Series A | $120M | Jan 2025 |
 Maxion Therapeutics | Series A | $16M | Feb 2024 |
 Ascend Gene & Cell Therapies | Series A | $132.5M | May 2023 |
 ODAIA | Series B | $25M | May 2023 |
Top Co-Investors
Forbion1 shared
Sofinnova Partners1 shared
NEA (New Enterprise Associates)1 shared
Norwest Venture Partners1 shared
UPMC Enterprises1 shared
OrbiMed1 shared
Threshold Ventures1 shared
Wittington Ventures1 shared
Abingworth1 shared
DCVC1 shared
4BIO Capital1 shared
Deerfield1 shared
Digitalis Ventures1 shared
LifeArc Ventures1 shared
BGF1 shared
Last updated: 16 April 2026